Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

RTTNews | il y a 229
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.

The European Commission is expected to announce a final decision in the coming months. FL and DLBCL are the two most common subtypes of B-cell non-Hodgkin lymphoma (B-NHL).

The positive CHMP opinion is supported by results from the Phase 1 ELM-1 and pivotal Phase 2 ELM-2 trials, which demonstrated robust, durable response rates and an acceptable safety profile of odronextamab in adults with R/R FL or R/R DLBCL. The EMA previously granted odronextamab Orphan Designation for both FL and DLBCL. Odronextamab is currently under clinical development and has not been approved by any regulatory authority.

Regeneron continues to evaluate the use of odronextamab as a monotherapy and in combination across earlier lines of therapy in challenging-to-treat lymphomas.

read more
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | il y a 195
Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews | il y a 376
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | il y a 957
U.S. Consumer Prices Climb 0.5% In January, More Than Expected

U.S. Consumer Prices Climb 0.5% In January, More Than Expected

Consumer prices in the U.S. increased by more than expected in the month of January, according to a report released by the Labor Department on Wednesday. The Labor Department said its consumer price index advanced by 0.5 percent in January after climbing by 0.4 percent in December. Economists had expected consumer prices to rise by 0.3 percent.
RTTNews | il y a 7h 17min
India Inflation Weakens More Than Forecast To Lowest Level In 5 Months

India Inflation Weakens More Than Forecast To Lowest Level In 5 Months

India's consumer price inflation slowed more than expected to a five-month low in January reinforcing expectations that the Reserve Bank of India will reduce interest rates further. The consumer price index registered an increase of 4.31 percent on a yearly basis in January, weaker than the 5.22 percent rise logged in December, official data revealed on Wednesday.
RTTNews | il y a 9h 32min